These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34757749)

  • 1. Mechanism-Based and Computational-Driven Covalent Drug Design.
    Luo YL
    J Chem Inf Model; 2021 Nov; 61(11):5307-5311. PubMed ID: 34757749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constructing Innovative Covalent and Noncovalent Compound Libraries: Insights from 3D Protein-Ligand Interactions.
    Xu X; Han W; Ning X; Zang C; Xu C; Zeng C; Pu C; Zhang Y; Chen Y; Liu H
    J Chem Inf Model; 2024 Mar; 64(5):1543-1559. PubMed ID: 38381562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation.
    Yu W; Weber DJ; MacKerell AD
    J Chem Theory Comput; 2023 May; 19(10):3007-3021. PubMed ID: 37115781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Covalent Ligands via Noncovalent Docking by Dissecting Covalent Docking Based on a "Steric-Clashes Alleviating Receptor (SCAR)" Strategy.
    Ai Y; Yu L; Tan X; Chai X; Liu S
    J Chem Inf Model; 2016 Aug; 56(8):1563-75. PubMed ID: 27411028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
    Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
    J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Covalent Inhibitors for Drug Design.
    Baillie TA
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13408-13421. PubMed ID: 27539547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
    Silva JRA; Cianni L; Araujo D; Batista PHJ; de Vita D; Rosini F; Leitão A; Lameira J; Montanari CA
    J Chem Inf Model; 2020 Mar; 60(3):1666-1677. PubMed ID: 32126170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing Irreversible Inhibitors--Worth the Effort?
    González-Bello C
    ChemMedChem; 2016 Jan; 11(1):22-30. PubMed ID: 26593241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy.
    Hoffer L; Saez-Ayala M; Horvath D; Varnek A; Morelli X; Roche P
    J Chem Inf Model; 2019 Apr; 59(4):1472-1485. PubMed ID: 30908019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent peptides and proteins for therapeutics.
    Berdan VY; Klauser PC; Wang L
    Bioorg Med Chem; 2021 Jan; 29():115896. PubMed ID: 33285408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent simulations of covalent/irreversible enzyme inhibition in drug discovery: a reliable technical protocol.
    Khan S; Bjij I; Olotu FA; Agoni C; Adeniji E; S Soliman ME
    Future Med Chem; 2018 Oct; 10(19):2265-2275. PubMed ID: 30273013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.
    Li Q; Chen Q; Klauser PC; Li M; Zheng F; Wang N; Li X; Zhang Q; Fu X; Wang Q; Xu Y; Wang L
    Cell; 2020 Jul; 182(1):85-97.e16. PubMed ID: 32579975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.
    Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy.
    Yuan M; Chu Y; Duan Y
    Front Chem; 2021; 9():691093. PubMed ID: 34291036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding Mode Prediction and Virtual Screening Applications by Covalent Docking.
    Scarpino A; Ferenczy GG; Keserű GM
    Methods Mol Biol; 2021; 2266():73-88. PubMed ID: 33759121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Statistical Survey on the Binding Constants of Covalently Bound Protein-Ligand Complexes.
    Li X; Liu Z; Li Y; Li J; Li J; Wang R
    Mol Inform; 2010 Jan; 29(1-2):87-96. PubMed ID: 27463851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.